Background: Recombinant therapeutic anti-CD20 monoclonal antibody (mAb) is used for the treatment of non-Hodgkin's lymphoma, a common B cell lymphoma constituting 80% of all lymphomas. Anti-CD20 mAb contains an Fc-linked biantennary glycan. Although, anti-CD20 monoclonal antibodies are being increasingly used for immunotherapy, their efficacy is limited in a section of patients with drug resistance to immunotherapy. There is a need to improve the efficacy by increasing the effector functions, such as the antibody-dependent cellular cytotoxicity (ADCC) activity of anti-CD20 monoclonal antibodies.
Results: We developed a simple and cost-effective approach to enhance ADCC effector activity in an in-house developed clone of anti-CD20 monoclonal antibody by increasing afucosylation in a new clone of Chinese Hamster Ovary (CHO) cells using 8X uridine, manganese, and galactose (UMG) to modulate the osmolality of the medium. The purified anti-CD20 monoclonal antibody from 8X UMG-containing medium showed a 2-fold increase in afucose content and 203% ADCC activity in comparison to control antibody.
Conclusions: Our study reports enhanced ADCC activity by modulating afucosylation using osmolality by altering simple feed additives in the culture medium.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532503 | PMC |
| http://dx.doi.org/10.1186/s43141-022-00421-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of dysphagia and its associations in patients with secondary progressive multiple sclerosis.
Mult Scler Relat Disord
December 2024
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Sina Hospital, Hasan Abad Sq., Tehran, Iran. Electronic address:
In this cross-sectional study in patients with secondary progressive multiple sclerosis receiving anti-CD20 monoclonal antibodies, we assessed complaint of dysphagia and evaluated their association with sex, age, disease duration, disability severity, and disease-modifying therapies (DMTs). The validated Persian version of Dysphagia in Multiple Sclerosis (DYMUS) questionnaire was used. A total of 66 patients were included.
View Article and Find Full Text PDFMicrosporidiosis in Patients with Autoimmune Diseases Undergoing Monoclonal Antibody Associated Therapy.
Mycopathologia
January 2025
Sorbonne Université, Inserm U1135, Centre d'Immunologie et de Maladies Infectieuses (Cimi-Paris), AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, 184 rue Faubourg Saint Antoine, 175012, Paris, France.
We present Enterocytozoon bieneusi infection in four patients with autoimmune diseases undergoing prolonged monoclonal antibody therapies. Two patients suffered from inflammatory bowel disease and received anti-TNF therapies, whereas two other patients suffered from systemic lupus erythematosus with renal involvement and received anti-CD20 or anti-BLyS protein therapies. Three out of four patients consulted for diarrhea with abdominal pain without intestinal inflammation or bleeding at the time of sampling.
View Article and Find Full Text PDFBackground: Rituximab is already a standard part of the treatment of patients with Waldenström's macroglobulinemia. However, a small proportion of patients develop intolerance to rituximab during administration or the treatment is not very effective. In these patients, we are faced with the question of whether another anti-CD20 monoclonal antibody can be used and what result will be achieved.
View Article and Find Full Text PDFThe novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells.
Hum Vaccin Immunother
December 2025
Department of Research and Development, ManySmart Therapeutics, Taipei, Taiwan.
Monoclonal antibodies enhance innate immunity, while bispecific T cell engager antibodies redirect adaptive T cell immunity. To stimulate both innate and adaptive mechanisms, we created a bifunctional eCD16A/anti-CD3-BFP adapter protein for combined use with clinically approved monoclonal IgG1 antibodies. The adaptor protein contains the extracellular domain of the human CD16A high-affinity variant, which binds the Fc domain of IgG1 antibodies, and an anti-human CD3 single-chain variable fragment that redirects T cell cytotoxicity.
View Article and Find Full Text PDFObinutuzumab-induced acute thrombocytopenia: a case report and literature review.
Front Oncol
December 2024
Department of Hematology, Peking University People's Hospital, National Clinical Research Center for Hematologic Diseases, Peking University Institute of Hematology, Beijing, China.
Background: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphomas. Thrombocytopenia typically occurs 1 to 2 weeks after administration. In rare cases, obinutuzumab can induce severe acute thrombocytopenia within days of infusion, a condition known as "obinutuzumab-induced acute thrombocytopenia (OIAT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!